Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Milestone Pharmaceuticals (Nasdaq: MIST) announced that CEO Joseph Oliveto will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The chat will be pre-recorded and accessible from September 13, 2021, at 7:00 am ET on Milestone's website. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and in Phase 2 trials for atrial fibrillation treatment.

MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23^rd Annual Global Investment Conference being held virtually on September 13-15, 2021.

The prerecorded fireside chat will become available on Monday, September 13, 2021 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the fireside chat will be available on the same website 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma. 

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301369385.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

When will Milestone Pharmaceuticals present at the H.C. Wainwright conference?

Milestone Pharmaceuticals will present at the H.C. Wainwright conference from September 13-15, 2021.

Who is participating in the fireside chat at the conference for Milestone Pharmaceuticals?

Joseph Oliveto, the CEO of Milestone Pharmaceuticals, will participate in the fireside chat.

When will the fireside chat be available to the public?

The fireside chat will be available on September 13, 2021, at 7:00 am ET.

What is the lead product candidate of Milestone Pharmaceuticals?

Milestone's lead product candidate is etripamil, currently in Phase 3 clinical trials.

What conditions does etripamil target?

Etripamil targets paroxysmal supraventricular tachycardia and is also in trials for atrial fibrillation.